US FDA launches pilot for one-day inspectional assessments across facilities

The U.S. Food and Drug Administration (FDA) has announced the launch of a pilot programme for one-day inspectional assessments as part of an initiative to make inspectional resources more targeted and efficient. The pilot, which began in April, involves shorter, focused screening assessments to complement standard FDA inspections.

“One-day inspections can strengthen our inspectional approach by focusing our time and resources where they are most needed—enhancing our overall effectiveness,” said FDA Commissioner Marty Makary, M.D., M.P.H. “For the FDA, the ability to conduct shorter, targeted assessments allows for broader surveillance coverage, enabling the agency to assess more facilities and gather critical insights without compromising regulatory rigor. For industry, these assessments can provide timely feedback while minimizing operational disruption, particularly for lower-risk establishments.”

The FDA stated that one-day inspectional assessments will also support the development of risk models across its programmes. Data collected through these assessments, including compliance themes, facility-specific risk scores, and differences between registered and actual operations, will be used to inform future oversight activities.

The pilot is being conducted across multiple FDA inspectorates, including human and animal foods, biologics, medical products, and clinical research programmes. Facilities are selected based on risk criteria such as product type, prior inspection outcomes, and operational characteristics.

As of late April 2026, the FDA has completed approximately 46 one-day assessments. Most assessments confirmed compliance, resulting in No Action Indicated (NAI) outcomes. Some assessments were extended beyond one day where significant observations were identified.

The FDA clarified that one-day inspectional assessments are not intended to replace standard inspections and will act as an additional tool within its existing framework. Investigators retain authority to expand the scope or duration of an assessment where required. The pilot does not represent a change in enforcement policy and does not apply to higher-risk or complex facilities requiring full inspection coverage.

“We are closely analyzing the operational and compliance data from these assessments—including trends in outcomes, risk signals, and investigator feedback to determine how this approach can enhance our broader inspectional strategy,” said FDA Associate Commissioner for Inspections and Investigations, Elizabeth Miller, Pharm.D.

The pilot will continue through fiscal year 2026, with further assessments planned across inspectorates. The FDA is developing evaluation metrics including inspection duration, escalation rates, and the utility of findings in risk-based decision-making.

Responding to the FDA’s pilot initiative, industry leaders shared their perspectives on its potential impact on pharmaceutical manufacturing, compliance practices, and regulatory oversight with Express Pharma:

Dr Ranjit Barshikar, CEO – QbD International, United Nations Advisor:

“This is a very positive initiative by US FDA, to assess operational & compliance data, to identify risk signals (based on Risk based inspections approach), during this one-day inspections. This will enhance FDA’s broader inspections strategy to plan for additional assessments of high risks organisations.”

Pharma expert AVPS Chakravarthi:

 “Though it looks like a positive step toward making inspections more focused and efficient, it will be important to ensure that faster assessments do not reduce the depth needed to maintain strong quality and compliance standards. And harmony needs to be maintained among all such inspections.”

Kaushik Desai, Executive Committee Member, Industrial Pharmacy Section, FIP:

“The FDA’s one-day inspection pilot will significantly streamline regulatory interactions for the Indian pharmaceutical industry, which hosts the highest number of FDA-registered plants outside the U.S. By focusing on shorter, targeted assessments, compliant Indian manufacturers can expect minimal operational disruption, allowing production schedules to remain largely unaffected compared to standard multi-day audits. This shift rewards facilities with strong compliance histories, potentially reducing the administrative burden on high-performing sites by leveraging data for predictive risk modeling. Conversely, the use of shorter, AI-targeted screenings means Indian firms must maintain rigorous standards, as “risk signals” are identified faster. Ultimately, this data-driven environment aims to strengthen India’s reputation as a reliable global supplier while refining FDA resource allocation. 

This initiative is expected to improve patient access to medicines, mitigate potential shortages, and incentivise manufacturers to uphold high-quality management standards supporting uninterrupted supply.” 

S M Mudda, Chairman IDMA Regulatory Affairs:

An interesting move by the US FDA toward more risk-based and intelligence-driven oversight. While MHRA and EU agencies had already adopted risk-based approaches for inspection planning, the FDA pilot appears to take this concept further operationally. It also reflects the growing global expectation that pharmaceutical quality systems should demonstrate continuous state of control and visibility.